Fractyl Health Inc., a leading metabolic therapeutics company, has announced a partnership with Bariendo Inc., an innovative obesity care platform. The two companies have signed a non-binding Letter of Intent to explore a collaboration centered on Fractyl's investigational procedure, Revita, as a sustainable solution for post-GLP-1 weight maintenance. This partnership aims to address the increasing demand for endoscopic alternatives that offer a holistic approach to maintaining weight loss after GLP-1 drug discontinuation. The collaboration will focus on preparing for the potential integration of Revita into Bariendo's clinical offerings, pending FDA approval, and will include initiatives such as clinical workflow design and provider education.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。